1. Managing Innovation Evista Case Morgane … Maël Bourguignon Jonathan Calvet Axel Caborderie

2. Summary I.INTRODUCTION –Background II.MARKET CONSTRAINTS AND PROBLEMATIC –Threats : Generics / « Me too » –Environmental constraints : Formularies / Laws –Problematic III.DEVELOPMENT PROCESS AND ORGANIZATION –Development process / Time to Market –« Heavyweight » management approach IV.CONCLUSION : –To go Further

3. 1876. Creation of ELI LILLY and Company by Colonel Eli Lilly, pharmaceutical chemist and Civil war veteran. Background

4. 1930-80. ELI LILLY continued to develop insulin product family and treatment of endocrine diseases. Background

5. 1920. First Blockbuster for treatment of diabetes: Insulin Background

6. 1950s. Development of Ceclor : top-selling antibiotic of the world. Background

7. 1980. Introduction of Humilin using recombinant DNA technology : improve diabetes treatment. Background

8. 1986. Commercialisation of Prozac : drug for central nervous system. Background

9. 1996. Zyprexa : Anti-psychotic for treatment of schizophrenia. Background

10. 1990-97. Restructuring and focus on fighting cancer and cardiovascular diseases : Launch of ReoPro, anti-platelet agent and Gemzar, oncology product. Background

11. 2005. Eli Lilly registered 14,6 billion $ of global revenues Background

12. The problematic Considering the increasing threats within the pharmaceutical industry, How can Eli Lilly remain competitive?

13. Conclusion Time to market : a better approach taking into account the market constraints. « Heavyweight » approach: give the priority to the future potential blockbuster.

14. Conclusion To go further : –Should we apply this approach to the commercialization of new drugs ? –On which criterions ? –For which costs ? –Should we have to delay or stop other projects ?